Back

What is the stroke risk threshold for anticoagulation to provide net benefit in atrial fibrillation? A Markov decision model analysis

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Stroke prevention Oral Anticoagulation EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Konsta Teppo

University of Turku, Turku (Finland)

6 More presentations in this session

Presentation thumbnail
Boosting anticoagulation adherence in atrial fibrillation and atrial flutter: the impact of a simple nudge strategy before elective electrical cardioversion
Doctor P. Mangas Palma (Porto, PT)
Abstract Slides Video
Presentation thumbnail
In-hospital outcomes of left atrial appendage (LAA) occlusion among cancer patients with atrial fibrillation: a nationwide US study
Associate Professor E. Leshem (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
Alcohol use disorder and initiation of oral anticoagulant therapy in patients with atrial fibrillation: a nationwide cohort study
Mr M. Vanhanen (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Extraction of Watchman device using a double transeptal approach
Doctor V. La Fazia (Austin, US)
Abstract Slides Video
Presentation thumbnail
Peri-device sealing and procedural outcomes of LAA closure: a comparative study of device types in patients with and without LAA isolation
Doctor H. Alessandrini (Luebeck, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Stroke prevention

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Stroke risk in low-risk patients with atrial fibrillation on oral anticoagulation therapy: Insights from a Swedish cohort
thumbnail
Congress Presentation
Timing of stroke risk reassessment in atrial fibrillation patients with CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study
thumbnail
Congress Presentation
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources